BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 4406686)

  • 1. Correlation between long-acting thyroid stimulator protector level and thyroid 131-I uptake in thyrotoxicosis.
    Adams DD; Kennedy TH; Stewart RD
    Br Med J; 1974 Apr; 2(5912):199-201. PubMed ID: 4406686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LATS protector and abnormal thyroid stimulation in diffuse toxic goitre.
    Stewart RD
    N Z Med J; 1975 Jan; 81(531):24. PubMed ID: 1055311
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of long-acting thyroid stimulator (LATS) and LATS protector on human thyroid adenyl cyclase activity.
    Kendall-Taylor P
    Br Med J; 1973 Jul; 3(5871):72-5. PubMed ID: 4740444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-acting thyroid stimulator (LATS) and long acting thyroid stimulator protector (LATS-P) in untreated thyrotoxicosis.
    Hardisty CA; Hanford L; Humphries H; Munro DS
    Clin Endocrinol (Oxf); 1981 Jun; 14(6):631-9. PubMed ID: 6895353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissociation of serum LATS activity and hyperfunction and autonomy of the thyroid gland in Graves' disease.
    Hennemann G; Dolman A; Docter R; De Reus A; Van Zijl J
    J Clin Endocrinol Metab; 1975 Jun; 40(6):935-41. PubMed ID: 1173367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transient thyrotoxicosis in an infant delivered to a long-acting thyroid stimulator (LATS)- and LATS protector-negative, thyroid-stimulating antibody-positive woman with Hashimoto's thyroiditis.
    Hoffman WH; Sahasrananan P; Ferandos SS; Burek CL; Rose NR
    J Clin Endocrinol Metab; 1982 Feb; 54(2):354-6. PubMed ID: 6119322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence that mouse thyroid stimulator does not stimulate the human thyroid gland.
    Adams DD; Kennedy TH; Stewart RD
    Aust N Z J Med; 1976 Aug; 6(4):300-4. PubMed ID: 1070985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LATS-protector activity in thyrotoxicosis measured by thyroidal intracellular colloid droplet formation.
    Shishiba Y; Miyachi Y; Takaishi M; Ozawa Y
    J Clin Endocrinol Metab; 1978 May; 46(5):841-8. PubMed ID: 262769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence that both long-acting thyroid stimulator and long-acting thyroid stimulator-protector stimulate the human thyroid gland.
    Holmes SD; Dirmikis SM; Martin TJ; Munro DS
    J Endocrinol; 1979 Feb; 80(2):215-21. PubMed ID: 220366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence to suggest that LATS protector stimulates the human thyroid gland.
    Adams DD; Kennedy TH
    J Clin Endocrinol Metab; 1971 Jul; 33(1):47-51. PubMed ID: 5558041
    [No Abstract]   [Full Text] [Related]  

  • 11. Lack of refractoriness to stimulation with long acting thyroid stimulator of thyroid hormone synthesis and thyroid hormone secretion in mice in vivo.
    Ikeda H; Nagataki S
    Acta Endocrinol (Copenh); 1983 Mar; 102(3):392-5. PubMed ID: 6829264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation between thyroid function and serum levels of long-acting thyroid stimulator.
    Davis JC; Hipkin LJ; Summers VK; Gimlette TM
    Acta Endocrinol (Copenh); 1975 Jul; 79(3):451-8. PubMed ID: 1173501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The assay of Graves' immunoglobulins: a comparison of different methods.
    Hardisty CA; Kendall-Taylor P; Atkinson S; Humphries H; Munro DS
    Clin Endocrinol (Oxf); 1983 Jun; 18(6):637-44. PubMed ID: 6136348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of radioablation of the thyroid gland in Graves' disease with high levels of long-acting thyroid stimulator (LATS).
    Volpé R; Desbarats-Schonbaum ML; Schonbaum E; Row VV; Ezrin C
    Am J Med; 1969 Feb; 46(2):217-26. PubMed ID: 5818477
    [No Abstract]   [Full Text] [Related]  

  • 15. Hemiaplasia of the thyroid with thyrotoxicosis.
    Mortimer PS; Tomlinson IW; Rosenthal FD
    J Clin Endocrinol Metab; 1981 Jan; 52(1):152-5. PubMed ID: 7451642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical applications of assays for thyrotropin-receptor antibodies in Graves' disease.
    Ginsberg J; von Westarp C
    CMAJ; 1986 May; 134(10):1141-7. PubMed ID: 2421862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of the long-acting thyroid stimulator (LATS) on radioiodine-labelled thyroxine and triiodothyronine in the thyroid of mice.
    Emrich D; von Toll-Jürgens KH; zur Mühlen A Von
    Endocrinology; 1970 Sep; 87(3):632-6. PubMed ID: 5424582
    [No Abstract]   [Full Text] [Related]  

  • 18. Detection and properties of TSH-binding inhibitor immunoglobulins in patients with Graves' disease and Hashimoto's thyroiditis.
    Endo K; Kasagi K; Konishi J; Ikekubo K; Okuno T; Takeda Y; Mori T; Torizuka K
    J Clin Endocrinol Metab; 1978 May; 46(5):734-9. PubMed ID: 45421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LATS protector, the human thyroid stimulator.
    Adams DD
    N Z Med J; 1975 Jan; 81(531):22-3. PubMed ID: 1055310
    [No Abstract]   [Full Text] [Related]  

  • 20. Proceedings: Studies on long-acting thyroid stimulator protector in serum containing long-acting thyroid stimulator.
    Dirmikis S; Munro DS
    J Endocrinol; 1975 Mar; 64(3):29P-30P. PubMed ID: 1173370
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.